Canada’s Valeant Pharmaceuticals’ affiliate has entered into an agreement to sell its equity interests in Dendreon Pharmaceuticals to China’s Sanpower Group for $819.9m.

Dendreon's Provenge was approved by the Food and Drug Administration (FDA) in April 2010 and is an autologous cellular immunotherapy (vaccine) for prostate cancer treatment.

Valeant Pharmaceuticals CEO Joseph Papa said: "With this sale, we are better aligning our product portfolio with Valeant's new operating strategy by exiting the urological oncology business, which is one of our non-core assets.

"We are pleased to take this step forward in our divestiture programme and are continuing to evaluate transactions to simplify our business and strengthen our balance sheet."

Provenge is an immunotherapy that takes the patient’s own immune cells and reprogrammes them to attack the advanced prostate cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"We are pleased to take this step forward in our divestiture programme and are continuing to evaluate transactions to simplify our business and strengthen our balance sheet."

By jumpstarting immune cells already in the body, it helps the patient to fight against cancer.

Valeant plans to use proceeds from the sale of Dendreon to repay term loan debt permanently under its senior secured credit facility.

The transaction is subject to customary closing conditions, including receipt of applicable regulatory approvals and is slated for completion in the first half of this year.

Valeant develops, manufactures and markets a range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.


Image: Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Gleason pattern 4. H&E stain. Photo: courtesy of Nephron.